Proactive Research analyst John Savin explains the investment case for Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), which directly sells a fully approved and patented oral iron product, Accrufer, into the large and lucrative US market.
He talks about the investment case, what new management has changed and the next crucial steps to reaching cash sustainability: gaining US reimbursement and building physician knowledge.